-

Meiji Pharma Asia Commences Operations in Singapore

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Toshiaki Nagasato) announced that its local subsidiary, Meiji Pharma Asia Pte. Ltd. (Headquarters: Singapore, Managing Director: Kensuke Hata) commenced operations in Singapore on April 1,2026. This subsidiary is intended to strengthen Meiji Seika Pharma’s presence and expand its business in the ASEAN region through the commercialization, marketing and distribution of pharmaceuticals, including vaccines.

Meiji Seika Pharma aims to become "a leading company in Asia in the field of infectious diseases" as part of the "Meiji Group 2026 Vision" targeting 2026. Leveraging nearly half a century of experience in manufacturing and marketing pharmaceuticals in Thailand and Indonesia, Meiji Seika Pharma will position Singapore as a hub for its business and commercial strategies across the ASEAN region, with the aim of further enhancing its influence and accelerating growth in the region.

Meiji Pharma Asia focuses on commercializing, marketing and distributing pharmaceuticals including vaccines, in the fields of infectious diseases, hematologic cancers, and lifestyle-related diseases. Through Meiji Pharma Asia, Meiji Seika Pharma intends to reliably supply pharmaceuticals and contribute to the health and well-being of the people in the region.

Company Overview

(1) Name: Meiji Pharma Asia Pte. Ltd.
(2) Location: Singapore
(3) Representative (Managing Director): Kensuke Hata
(4) Incorporation Type: Private Limited Company
(5) Business Description: Commercialization, marketing and distribution of pharmaceuticals including vaccines, etc.
(6) Capital: 1.5 million Singapore Dollars
(7) Date of Establishment: December 10, 2025
(8) Date of Commencement of Operations: April 1, 2026
(9) Shareholder Composition: Wholly owned subsidiary of Meiji Seika Pharma Co., Ltd.

Contacts

For further information, please contact:
Kensuke Hata
Meiji Pharma Asia Pte. Ltd.
E-mail: mpa-contact@meiji.com

Industry:

Meiji Seika Pharma Co., Ltd.

Release Summary
Meiji Pharma Asia commenced operations in Singapore to strengthen ASEAN presence via marketing and distribution of pharmaceuticals including vaccines.
Release Versions
English

Contacts

For further information, please contact:
Kensuke Hata
Meiji Pharma Asia Pte. Ltd.
E-mail: mpa-contact@meiji.com

More News From Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma reports positive Phase III Integral-1 results for nacubactam, a novel β-lactamase inhibitor, in cUTI/AP — published in The Lancet....

Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma will present 10 studies on Nacubactam at ESCMID Global 2026 including Phase III Integral-2 results in patients with CRE infections....

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma invests in Centivax to advance a universal vaccine platform, backing Phase 1 Centi-Flu 01 and a broad pipeline....
Back to Newsroom